Introduction & Liver Forum Update

Katherine Barradas
Forum for Collaborative Research
## Agenda

**Moderator: Veronica Miller, Forum for Collaborative Research**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter/Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM</td>
<td>Liver Forum Updates</td>
<td>Katherine Barradas, Forum for Collaborative Research</td>
</tr>
<tr>
<td>11:10 AM</td>
<td>NIMBLE Update</td>
<td>Tania Kamphaus, Foundation for the National Institutes of Health</td>
</tr>
<tr>
<td>11:20 AM</td>
<td>LITMUS Update</td>
<td>Richard Torstenson, AbbVie</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Recent NASH Clinical Trial Results &amp; Implications</td>
<td>Mazen Noureddin, Cedars-Sinai Medical Center</td>
</tr>
<tr>
<td>11:55 AM</td>
<td>FDA Update</td>
<td>Ruby Mehta, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>EMA Reflection Paper Update</td>
<td>Katherine Barradas, Forum for Collaborative Research***</td>
</tr>
<tr>
<td>12:05 PM</td>
<td>Global Liver Institute Updates</td>
<td>Donna Cryer, Global Liver Institute</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Group Discussion</td>
<td>All</td>
</tr>
<tr>
<td>12:55 PM</td>
<td>Future Directions &amp; Next Steps</td>
<td>Veronica Miller, Forum for Collaborative Research</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Adjourn Webinar</td>
<td></td>
</tr>
</tbody>
</table>
Overview of the Liver Forum

- **What:** a platform for ongoing multi-stakeholder dialogue to identify barriers, prioritize research and identify solutions to accelerate therapeutic development for NAFLD/NASH

- **How:** provide a neutral, independent, safe space for discussion and deliberation across stakeholder groups
  - Focus on developing consensus, increasing synergy and collaboration, and reducing duplication and uncertainty
  - Ongoing working group activity throughout the year anchored by larger project events
  - Active & engaged participation
Rules of the [Zoom] Room

- **Presentations, discussions, comments, and questions are not for attribution**
  - Participants speak as individuals and express views that may not represent those of their organizations
  - Recording by participants is not permitted. Slides will be available on our website pending speaker permission.

- **Participation Reminder (Forum Operating Principles)**
  - We restrict participation to experts with the necessary scientific knowledge from organizations or entities with a clear commitment to advancing the diagnostic and therapeutic field of the disease area of the project they participate in, whether they be from government, academia, industry or community. Only in this way can we achieve the effectiveness and productivity needed to add value to the field. The Forum is not a venue for marketing and/or investment experts.
Recent Activities & Accomplishments

- **Accepted: NASH Cirrhosis Manuscript #1**
  
  *Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum*

  Mazen Noureddin, Jean Chan, Katherine Barradas, Lara Dimick-Santos, Elmer Schabel, Stephanie Omokaro, Frank Anania, Robert Myers, Veronica Miller, Arun Sanyal, Naga Chalasani, for the Liver Forum NASH Cirrhosis Working Group

  *In Press, Gastroenterology, [https://doi.org/10.1053/j.gastro.2020.04.039](https://doi.org/10.1053/j.gastro.2020.04.039)*

- **Accepted: Standard of Care Lifestyle Manuscript**

  *Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum*

  Oliver Glass, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Katherine Barradas, Jörn M. Schattenberg, Veronica Miller, Sven Francque, Manal F. Abdelmalek, for the Liver Forum Standard of Care Working Group

# Working Group Details

<table>
<thead>
<tr>
<th>Working Group</th>
<th>Chairs</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Standardization</td>
<td>Joanne Imperial &amp; Andrew Muir</td>
<td>Completed</td>
</tr>
<tr>
<td>Case Definitions</td>
<td>Stephen Harrison &amp; Sophie Megnien</td>
<td>Completed</td>
</tr>
<tr>
<td>Standard of Care: Lifestyle</td>
<td>Manal Abdelmalek &amp; Sven Francque</td>
<td>To be Assessed</td>
</tr>
<tr>
<td>Estimands in NASH</td>
<td>Peter Mesenbrink &amp; Veronica Miller</td>
<td>Active/ Closed</td>
</tr>
<tr>
<td>Standard of Care: Comorbidities</td>
<td>Raluca Pais &amp; Vlad Ratziu</td>
<td>Active/ Open</td>
</tr>
<tr>
<td>Pediatric Issues</td>
<td>Joel Lavine &amp; Miriam Vos</td>
<td>Active/ Open</td>
</tr>
<tr>
<td>NASH Cirrhosis</td>
<td>Naga Chalasani &amp; Arun Sanyal</td>
<td>Active/ Open</td>
</tr>
</tbody>
</table>

All **ACTIVE/ OPEN** working groups welcome additional members!

To join, email me at kbarradas@forumresearch.org
Upcoming Webinars

Liver Forum Histology Series

- **Session 1**: Best Practices for Increasing Reliability of Liver Biopsies in NASH Clinical Trials
  
  *Tuesday, September 1, 2020; 12:00pm – 2:00pm ET*

- **Session 2**: Innovations in Liver Biopsy Assessment - Utilizing Digital Methods and AI Technology
  
  Date TBD (October 2020)

- **Session 3**: Causality Assessment for Suspected DILI in NASH Clinical Trials - Determining When to Biopsy
  
  Date TBD (November or December 2020)

- Additional sessions being considered for development
Sponsors

Diamond Sponsor:

NOVARTIS

The following sponsors contribute at their assigned membership levels:

Albireo
ALIGOS THERAPEUTICS
Alimentiv
Allergan
altimmune
Boehringer Ingelheim
Bristol-Myers Squibb
ChemomAb
COVANCE SOLUTIONS MADE REAL
EA Pharma Co., Ltd.
Echosens
ENANTA Pharmaceuticals
ENYO PHARMA
FIBRONOSTICS
Galectin Therapeutics
Sponsors
Sponsors

Thank You!